Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

ElevateBio is a technology-driven genetic medicines company, accelerating access to cutting-edge technologies, end-to-end manufacturing capabilities, and expertise to advance the cell and gene therapy industry. The company's integrated ecosystem of technologies and capabilities enables the discovery, development, manufacturing, and commercialization of a broad spectrum of cell and gene therapies and regenerative medicines.

Clare Murray

ElevateBio

AC Immune SA is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. It integrates diagnostic and therapeutic candidates in its pipeline.

AC Immune SA

Affimed is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies using its ROCK® (Redirected Optimized Cell Killing) platform.

Affimed

Therini Bio, Inc. | 1,720 followers on LinkedIn. Immunotherapies for NEUROINFLAMMATION in diseases driven by vascular dysfunction  | Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. The Company is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer’s disease (AD) and Diabetic Macular Edema (DME), where destructive neuroinflammation plays a central role in the disease process. The foundational science was licensed based on technology discovered in Katerina Akassoglou’s, Ph.D., laboratories at the Gladstone Institutes at the University of California San Francisco (UCSF) and formerly the University of California San Diego (UCSD).

Professor @ Gladstone & UCSF | Neuroimmunology, Neuroscience, Vascular Biology

Katerina Akassoglou

Head of Translational Sciences at Therini Bio

Aaron Kantor

General Partner & Managing Director at DFV | Healthcare VC, Entrepreneur, & Board Director

Sourav Kole

Biotech executive, company builder and board member

Tara Nickerson

Therini Bio, Inc.

Congrats to Therini founder Katerina Akassoglou and her collaborators on this significant research published today in Nature. This study further highlights the importance of therapies targeting neuroinflammation resulting from fibrin, such as those currently being developed by Therini for Alzheimer's and retinal diseases. https://lnkd.in/g8Y-akS7

Therini Bio team at ARVO this week shared updates on our pioneering approach to halt chronic neuroinflammation in diseases caused by vascular injury. Aaron Kantor , Joel Naor, MD, MSc, MBA #ARVO2024 #neuroinflammation #fibrin https://lnkd.in/g-6wdneD

Further research demonstrating how fibrin triggers neuroinflammation by JaeKyu Ryu and Therini Founder Katerina Akassoglou . Therini is developing a first-in-class immunotherapy, currently in Phase 1 studies, to neutralize the toxic effects of fibrin.

Congrats to Therini Bio's scientific founder Katerina Akassoglou on this well-deserved recognition! Stemming from this pioneering research, Therini is developing THN391 to target fibrin-driven neuroinflammation in diseases involving loss of vascular integrity including Alzheimer's disease and Diabetic Macular Edema.

We celebrate Katerina Akassoglou for her pioneering research around the role of fibrin-driven inflammation underlying a range of diseases that involve vascular dysfunction, and discovery of a fibrin-targeting immunotherapy approach to protect against neuroinflammation and neurodegeneration.

Metric
Company Name	Therini Bio	ElevateBio	AC Immune SA	Affimed
Symbol
MSH ID	COM:THERINIBIO	BIO:ELEVATE	COM:ACIMMUNE	COM:AFFIMED
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	CH	DE
Stage		Series D
Employee Count		462		105
Website	therinibio.com	elevate.bio	acimmune.com	affimed.com
LinkedIn	therinibio	elevatebio		affimed-ag
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		7.15K
Web Traffic Growth		-0.51
Valuation
Raised Capital		401M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

THER

COM:THERINIBIO

Therini Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue